AbbVie and Medtronic's Dividend Growth Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 7h ago
0mins
Should l Buy ABBV?
Source: NASDAQ.COM
- AbbVie Dividend Performance: AbbVie boasts a dividend yield of 2.98% and has increased its quarterly dividend for 54 consecutive years, raising it by 5.5% to $1.73 per share in 2023, demonstrating strong cash flow and sustainable dividend growth potential.
- Medtronic Market Growth: In Q2 of fiscal 2026, Medtronic reported $9 billion in revenue, a 6.6% year-over-year increase, with EPS rising 8% to $1.07, and it anticipates a 5.5% revenue growth, showcasing its successful pivot into smart devices.
- Importance of R&D Investment: Both companies prioritize R&D, with AbbVie investing over $19 billion in 2023 to ensure ongoing product innovation, while Medtronic focuses on new product development to maintain competitiveness despite dividend payout pressures.
- Market Competitive Advantage: The size and diversification of AbbVie and Medtronic allow them to sustain revenue growth across various market segments, with AbbVie's oncology products accounting for 11% of its revenue and Medtronic planning to spin off its diabetes business to optimize resource allocation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 253.26 USD with a low forecast of 218.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
15 Buy
7 Hold
0 Sell
Moderate Buy
Current: 225.640
Low
218.00
Averages
253.26
High
289.00
Current: 225.640
Low
218.00
Averages
253.26
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie Expected to Report 23% Earnings Surge in Q4
- Earnings Growth Expectation: AbbVie is expected to report a 23% increase in Q4 earnings on February 4, with EPS projected at $2.65 and revenue anticipated to rise 8.7% to $16.41 billion, indicating strong market performance.
- Expense Impact Analysis: The company expects to incur $1.3 billion in IPR&D and milestone expenses in Q4, leading to a -$0.71 impact on both GAAP and non-GAAP diluted EPS, reflecting ongoing investment in research and development.
- Market Competition Pressure: Despite AbbVie's strong performance this year, analysts note that intensifying competition from JNJ's Tremfya will make IBD trial results critical for the company's future, potentially affecting its market share.
- Future Growth Strategy: AbbVie is projected to pursue more deals by 2026 to enhance growth into the 2030s, particularly in complementing its obesity asset with a partner molecule, demonstrating a proactive approach to future market opportunities.
See More
Market Movements Ahead of U.S. Mining Conference
- Mining Stocks Surge: Ahead of the upcoming U.S. mining conference, MP Materials saw a 9.3% increase, with a nearly 30% rise year-to-date in 2026, indicating heightened market interest and demand for critical minerals, which may drive future investments and expansions for the company.
- Software Sector Decline: The S&P Software and Services sector dropped nearly 4% on Tuesday, with Cognizant plummeting 10%, reflecting investor concerns over the impact of artificial intelligence, which could undermine confidence in software companies and affect their growth potential moving forward.
- Walmart Hits $1 Trillion Market Cap: Walmart crossed the $1 trillion market cap for the first time on Tuesday, with shares up 25% over the past three months, indicating a strong recovery in the retail sector under new CEO John Furner, which may attract more investor interest.
- Biotech Earnings Reports Ahead: Eli Lilly and AbbVie are set to report earnings on
See More
Analysis and Outlook: A New Decline in Software Performance
Market Trends: The software market is experiencing a significant selloff, indicating a downturn in investor confidence.
Company Focus: Anthropic, a key player in the AI sector, is highlighted amidst the broader market challenges.
See More
Upcoming Earnings Reports and Employment Data
- Earnings Focus: Alphabet, Google's parent company, is set to report its fourth-quarter earnings after market close, with investors keenly observing whether the momentum around the Gemini project translates into tangible growth, which could significantly impact the company's market performance.
- Stable Ad Sales: Analysts indicate that Alphabet's core search business remains robust, with ad sales insulated from any significant shifts towards emerging technologies like Open AI's Chat GPT, providing a stable revenue foundation for the company.
- Impact of AI Tools: New AI-driven tools launched across Google's applications are expected to enhance ad targeting and personalization, potentially providing additional growth momentum for YouTube and further strengthening its competitive position in the market.
- Pharma Sector Updates: Pharmaceutical companies including Eli Lilly, AbbVie, and Novo Nordisk are also reporting earnings on the same day, with Eli Lilly's management noting that pricing is becoming more predictable, although volume remains uncertain, which could affect future margins and market strategies.
See More
Healthcare Stocks Show Dividend Growth Potential
- AbbVie's Dividend Performance: AbbVie boasts a dividend yield of 2.98% and has increased its quarterly dividend for 54 consecutive years, raising it by 5.5% to $1.73 per share in 2023, demonstrating strong cash flow and consistent dividend growth capability.
- Strong Financial Performance: AbbVie reported third-quarter revenue of $15.8 billion, a 9% year-over-year increase, although earnings per share fell 38% to $1.86, its investments in oncology are expected to lay the groundwork for future growth and enhance market competitiveness.
- Medtronic's Market Position: Medtronic, the largest stand-alone medical device maker with a market cap of $132 billion, reported second-quarter revenue of $9 billion, up 6.6% year-over-year, and forecasts a 5.5% revenue increase in 2026, indicating sustained growth potential in the medical device sector.
- Sustainability of Dividend Growth: With dividend payout ratios of 58% for AbbVie and 69% for Medtronic, both companies maintain relatively high ratios; however, due to strong free cash flow and ongoing revenue growth, they are expected to sustain their dividend payments, bolstering investor confidence.
See More
AbbVie and Medtronic's Dividend Growth Potential
- AbbVie Dividend Performance: AbbVie boasts a dividend yield of 2.98% and has increased its quarterly dividend for 54 consecutive years, raising it by 5.5% to $1.73 per share in 2023, demonstrating strong cash flow and sustainable dividend growth potential.
- Medtronic Market Growth: In Q2 of fiscal 2026, Medtronic reported $9 billion in revenue, a 6.6% year-over-year increase, with EPS rising 8% to $1.07, and it anticipates a 5.5% revenue growth, showcasing its successful pivot into smart devices.
- Importance of R&D Investment: Both companies prioritize R&D, with AbbVie investing over $19 billion in 2023 to ensure ongoing product innovation, while Medtronic focuses on new product development to maintain competitiveness despite dividend payout pressures.
- Market Competitive Advantage: The size and diversification of AbbVie and Medtronic allow them to sustain revenue growth across various market segments, with AbbVie's oncology products accounting for 11% of its revenue and Medtronic planning to spin off its diabetes business to optimize resource allocation.
See More
AbbVie Expected to Report 23% Earnings Surge in Q4
- Earnings Growth Expectation: AbbVie is expected to report a 23% increase in Q4 earnings on February 4, with EPS projected at $2.65 and revenue anticipated to rise 8.7% to $16.41 billion, indicating strong market performance.
- Expense Impact Analysis: The company expects to incur $1.3 billion in IPR&D and milestone expenses in Q4, leading to a -$0.71 impact on both GAAP and non-GAAP diluted EPS, reflecting ongoing investment in research and development.
- Market Competition Pressure: Despite AbbVie's strong performance this year, analysts note that intensifying competition from JNJ's Tremfya will make IBD trial results critical for the company's future, potentially affecting its market share.
- Future Growth Strategy: AbbVie is projected to pursue more deals by 2026 to enhance growth into the 2030s, particularly in complementing its obesity asset with a partner molecule, demonstrating a proactive approach to future market opportunities.
See More
Market Movements Ahead of U.S. Mining Conference
- Mining Stocks Surge: Ahead of the upcoming U.S. mining conference, MP Materials saw a 9.3% increase, with a nearly 30% rise year-to-date in 2026, indicating heightened market interest and demand for critical minerals, which may drive future investments and expansions for the company.
- Software Sector Decline: The S&P Software and Services sector dropped nearly 4% on Tuesday, with Cognizant plummeting 10%, reflecting investor concerns over the impact of artificial intelligence, which could undermine confidence in software companies and affect their growth potential moving forward.
- Walmart Hits $1 Trillion Market Cap: Walmart crossed the $1 trillion market cap for the first time on Tuesday, with shares up 25% over the past three months, indicating a strong recovery in the retail sector under new CEO John Furner, which may attract more investor interest.
- Biotech Earnings Reports Ahead: Eli Lilly and AbbVie are set to report earnings on
See More
Analysis and Outlook: A New Decline in Software Performance
Market Trends: The software market is experiencing a significant selloff, indicating a downturn in investor confidence.
Company Focus: Anthropic, a key player in the AI sector, is highlighted amidst the broader market challenges.
See More
Upcoming Earnings Reports and Employment Data
- Earnings Focus: Alphabet, Google's parent company, is set to report its fourth-quarter earnings after market close, with investors keenly observing whether the momentum around the Gemini project translates into tangible growth, which could significantly impact the company's market performance.
- Stable Ad Sales: Analysts indicate that Alphabet's core search business remains robust, with ad sales insulated from any significant shifts towards emerging technologies like Open AI's Chat GPT, providing a stable revenue foundation for the company.
- Impact of AI Tools: New AI-driven tools launched across Google's applications are expected to enhance ad targeting and personalization, potentially providing additional growth momentum for YouTube and further strengthening its competitive position in the market.
- Pharma Sector Updates: Pharmaceutical companies including Eli Lilly, AbbVie, and Novo Nordisk are also reporting earnings on the same day, with Eli Lilly's management noting that pricing is becoming more predictable, although volume remains uncertain, which could affect future margins and market strategies.
See More
Healthcare Stocks Show Dividend Growth Potential
- AbbVie's Dividend Performance: AbbVie boasts a dividend yield of 2.98% and has increased its quarterly dividend for 54 consecutive years, raising it by 5.5% to $1.73 per share in 2023, demonstrating strong cash flow and consistent dividend growth capability.
- Strong Financial Performance: AbbVie reported third-quarter revenue of $15.8 billion, a 9% year-over-year increase, although earnings per share fell 38% to $1.86, its investments in oncology are expected to lay the groundwork for future growth and enhance market competitiveness.
- Medtronic's Market Position: Medtronic, the largest stand-alone medical device maker with a market cap of $132 billion, reported second-quarter revenue of $9 billion, up 6.6% year-over-year, and forecasts a 5.5% revenue increase in 2026, indicating sustained growth potential in the medical device sector.
- Sustainability of Dividend Growth: With dividend payout ratios of 58% for AbbVie and 69% for Medtronic, both companies maintain relatively high ratios; however, due to strong free cash flow and ongoing revenue growth, they are expected to sustain their dividend payments, bolstering investor confidence.
See More
AbbVie and Medtronic's Dividend Growth Potential
- AbbVie Dividend Performance: AbbVie boasts a dividend yield of 2.98% and has increased its quarterly dividend for 54 consecutive years, raising it by 5.5% to $1.73 per share in 2023, demonstrating strong cash flow and sustainable dividend growth potential.
- Medtronic Market Growth: In Q2 of fiscal 2026, Medtronic reported $9 billion in revenue, a 6.6% year-over-year increase, with EPS rising 8% to $1.07, and it anticipates a 5.5% revenue growth, showcasing its successful pivot into smart devices.
- Importance of R&D Investment: Both companies prioritize R&D, with AbbVie investing over $19 billion in 2023 to ensure ongoing product innovation, while Medtronic focuses on new product development to maintain competitiveness despite dividend payout pressures.
- Market Competitive Advantage: The size and diversification of AbbVie and Medtronic allow them to sustain revenue growth across various market segments, with AbbVie's oncology products accounting for 11% of its revenue and Medtronic planning to spin off its diabetes business to optimize resource allocation.
See More
